Obsessive compulsive disorder: Serotonin and beyond

World Journal of Biological Psychiatry

Volumn 1, Issue 2, 2000, Pages 92-100

  Zohar, J ^a   Chopra, M ^a   Sasson, Y ^a   Amiaz, R ^a   Amital, D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

autoimmune mechanisms; brain circuitry; cognitive behavioural therapy; functional brain imaging; Obsessive Compulsive Disorder; pharmacological challenge; Selective Serotonin Reuptake Inihibitor; serotonergic processes

Indexed keywords

DOPAMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

CLASSIFICATION; HUMAN; METABOLISM; OBSESSIVE COMPULSIVE DISORDER; REVIEW;

DOPAMINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN;

EID: 0034175432     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970009150571     Document Type: Article

References (67)

1. Altemus M, Piggott T, L'Heureux F, et al (1993) Cerebrospinal fluid somatostatin in obsessive-compulsive disorder. Am J Psychiatry 15:460-464.
2. Altemus M, Swedo SE, Leonard B, et al (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessivecompulsive disorder with clomipramine. Arch Gen Psychiatry 51:794-803.
3. Ananth J, Pecknold JC, Van Den Steen N and Engelsman F (1981) Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress. Neuropsychopharmacology 5:257-262.
4. Barr, LC, Goodman WK, Price LH. McDougle CJ, Charney DS (1992) The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies. J Clin Psychiatry 4:17s-28s.
5. Barr LC, Goodman WK, Price LH (1993) The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 8:79s-82s.
6. Barr LC, Goodman WK, McDougle CJ et al (1994) Tryptophan depletion in patients with obsessive compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51:309-317.
7. Bastani B, Arora RC, Meltzer HY (1991). Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry 30:131-139.
8. Catapano F, Moneleone P, Fuschino A, et al (1992) Melatonin and Cortisol secretion in patients with primary obsessive-compulsive disorder. Psychiatry Res 44:217-225.
9. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR (1988) Serotonin function in obsessive-compulsive disorder: Arch Gen Psychiatry 45:177-185.
10. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive compulsive disorder. Psychopharmacol Bull 26 279-284.
11. Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive compulsive disorder (1991). Arch Cen Psychiatry 48:730-738.
12. DeVeaugh Ceiss J, Landau P, Katz R (1989) Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Ann 19:97.
13. Fernandez CE and Lopez-lbor JJ (1967) Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso Esp Neurol Psiquitar Cienc Afines 26:119-147.
14. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M (1985) Clomipramine treatment of childhood obsessive compulsive disorder: A double-blind controlled study. Arch Cen Psychiatry 42:977.
15. Goodman WK, Price LH, Rasmussen SA (1989) Efficacy of fluvoxamine in obsessive compulsive disorder: A double-blind comparison of fluvoxamine and placebo. Arch Gen Psychiatry 46:36-40.
16. Goodman Wk, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47:577-585.
17. Goodman WK, McDougle C, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GK (1995) M-Chlorophenylpiperazine in patients with obsessive compulsive disorder: absence of symptom exacerbation: Biol Psychiatry 38:138-149.
18. Gorman JM, Liebowitz MR, Fyer AJ, et al (1985) Lactate infusions in obsessive-compulsive disorder: Am J Psychiatry 142:864-866.
19. Gorman JM, Fyer AJ, Liebowitz MR (1987) Pharmacologic provocation of panic attacks. In H. Y. Meltzaer (Ed), Psychopharmacology, the third generation of progress, Raven Press, New York.
20. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard R, Mendels J, Rasmussen SA, White K (1993) Double blind comparison of three doses of sertraline and placebo in the treatment of outpatients with obsessive compulsive disorder. 1993a: 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, pp 18-19.
21. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard R, McElroy S, Mendels J, Rasmussen SA, White K, Flicer C, Sikes C (1993) Long term sertraline treatment of obsessive compulsive disorder: A 52-week double blind comparative study versus placebo. 1993b. 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, pp. 20-21.
22. Havlicck V, Rezek M, Friesen H (1976) Somatostatin and thyrotropin releasing hormone: central effects on sleep and motor systems. Pharmacol Biochem Behav 4:455-459.
23. Hewlett WA, Vinogradov S, Martin K, Berman S, Czernansky JG (1992) Fenfluramine stimulation of prolactin in obsessive compulsive disorder: Psychiatry Res 42, 81-92.
24. Hollander E, DeCaria CM, Gully R, et al (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenyl-piperazine in obsessive-compulsive disorder: Psychiatry Res 36:161-177.
25. Hollander E, DeCaria CM, Nitescu A, et al (1992) Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and health volunteers. Arch Gen Psychiatry 49:21-28.
26. lenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Sumergrad P, Seymour R, Ricciardi J (1990) A controlled trial of fluvoxamine in obsessive compulsive disorder. Am J Psychiatry 1990a, 147:1209-1215.
27. Kim SW, Dysken MW, Pandey GN, Davis JM (1991) Platelet 3H-imipramine binding sites in obsessive-compulsive disorder. Arch Gen Psychiatry 48:548-555.
28. Leckman JF, Goodman WK, North WG, et al (1994) Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Arch Gen Psychiatry 51:782-792.
29. Leonard H, Swedo S, Koby E, Rapoport JL, Lenane M, Cheslow D, Hamburger S (1989) Treatment of obsessive compulsive disorder with clomipramine and desmethylimipramine in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 46:1088-1092.
30. Leonard H, Swedo S, Lenane M, et al (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder: Arch Gen Psychiatry 50:922-927.
31. Lucey JV, Butcher G, Clare AW, et al (1993) Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity. Am J Psychiatry 150:961-962.
32. Lydiard RB, Ballenger JC, Ellinwood E, et al (1990) CSF monamine metabolites in obsessive-compulsive disorder. Proceedings, 143rd annual meeting of the American Psychiatric Association. May 1990, New York.
33. Mallya GK, White K, Waternaux C, Quay S (1992) Short and longterm treatment of OCD with fluvoxamine. Ann Clin Psychiatry 4:77-80.
34. Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB (1992) Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 42:41-51.
35. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 136:1-25.
36. Mavissakalian M, Turner SM, Michelson L Jacob R (1985) Tricyclic antidepressants in obsessive compulsive disorder: Antiobsessional or antidepressant agents? Am J Psychiatry 142:572.
37. McDougle CJ, Goodman WK, Price LH, et al (1990) Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 147:650-654.
38. Montgomery SA (1980) Clomipramine in obsessional neurosis: A placebo controlled trial. Pharm Med 1:89.
39. Montgomery SA, Mclntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ (1993) A double-blind, placebo controlled study of fluoxetine in patients with DSM-III-R obsessive compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3:143-152.
40. Montgomery SA (1998) Citalopram treatment of obsessive compulsive disorder: results from a double-blind placebocontrolled study. Presented at the 37th Annual Meeting of the American College of Neuropsychopharmacology, Las Croaloas, Puerto Rico, December 1998.
41. Murphy DL, Siever LJ, Insel TR (1985) Therapeutic responses to tricyclic antidepressants and related drugs in non-affective disorder patient population. Progress in Neuropsychopharmacology and Biol Psychiatry pp 3-13.
42. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 98:275-282.
43. Pato MT, Zohar-Kadouch RC, Zohar J, Murphy DL (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psychiatry 145:1521-1525.
44. Perse TL, Greist JH, Jefferson RH, Rosenfeld R and Dar R: Fluvoxamine treatment of obsessive compulsive disorder. Am J Psychiatry 1987;144:1543-1548.
45. Pigott TA, Zohar J, Hill JL, et al (1991) Metergoline blocks the behavioral and neuroendocrine effects of orally administered mchlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 29:418-426.
46. Pigott TA, Grady TA, Bernstein SE, et al (1992) A comparison of oral and IV m-CPP in patients with obsessive compulsive disorder. Biol Psychiatry 31:173A.
47. Pigott TA, Hill JL, Crady TA. et al (1993) A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 33:3-14.
48. Pitman RK (1989) Animal models of compulsive behaviour. Biol Psychiatry 26:189-198.
49. Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR (1987) Treatment of severe obsessive compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059.
50. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS (1987) Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology 93:308-313.
51. Roy BF, Benkelfat C, Hill JL, et al (1994) Serum antibody for somatostatin: 14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis and advanced HIV infection. Biol Psychiatry 35:334-344.
52. Sandyk R (1992) Tryptophan in neuropsychiatric disorders: Internat J Neuroscience 67:127-144.
53. Steiner M, Oakes R, Gergel IP, Wheadon DE (1994) Predictors of response to paroxetine therapy in OCD. APA Annual Meeting, Philadelphia, Pennsylvania, 1994.
54. Swedo SE, Leonard H, Shapiro MB, et al (1993) Sydenham's chorea: physical and psychological symptoms of St Vitus' dance. Paediatrics 91:706-713.
55. Thoren P, Asberg M, Gronholm B, Jornestedt L, Traskman L (1980) Clomipramine treatment of obsessive compulsive disorder. A controlled clinical trial. Arch Gen Psychiatry 37:1281-1285.
56. Tollefson GD, Rampey AH, Potvin JH (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry 51:559-567.
57. Vitiello B, Shimon H, Behar D, Stoff D, Bridger WH, Friedman E (1991) Platelet imipramine binding and serotonin upake in obsessive-compulsive patients. Acta Psychiatr Scand 84:29-32.
58. Volavka J, Neziroglu F, Yaryura-Tobias JA (1985) Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Res 14:85-93.
59. Weizman A, Carmi M, Hermesh H, Shahar A, Apter A, Tyano S, Rehavi N (1986) High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessivecompulsive patients. Am J Psychiatry 143:335-339.
60. Weizman A, Zohar J, Insel TR (1991) Biological markers in obsessive-compulsive disorder. In J.
61. Weizman R, Hermesh H, Karp M, et al (1993) The platelet benzodiazepine receptor is unaltered in obsessive-compulsive disorder. Clin Neuropharmacol 16:211-215.
62. Westenberg HGM, DE Leeuw AS, Den Boer JA (1992) Serotonin reuptake blockers in obsessive compulsive disorder: A controlled trial with fluvoxamine. Proceedings 18th CINP Congress, Nice 1992, pp 116.
63. Wheadon DE, Bushnell WD and Steiner M (1993) A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of OCD. Annual Meeting of the American College of Neuropsychopharmacology 1993.
64. Zohar J, Insel TR, Rasmussen S (Eds) The psychobiology of obsessive-compulsive disorder. Springer, New York.
65. Zohar J, Insel TR, Zohar-Kadouch RC, Murphy DL (1988a) Serotonergic role in obsessive-compulsive disorder. In A. R. Liss (Ed), Progress in catecholamine research, Part C: Clinical aspects.
66. Zohar J and Insel T (1987a) Obsessive compulsive disorder: Psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 22:667-687.
67. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987c). Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Arch Gen Psychiatry 44:946-951.